OkaiDx Cancer Early Detection Blood Test

Booth No: M709

Characteristic

OkaiDx is YD Bio's cancer diagnostics brand, built on exclusive licenses from EG BioMed covering DNA methylation technology for pancreatic cancer (U.S. Patent No. 12,258,636 B2) and breast cancer (U.S. Patent No. 12,203,140 B2). Using only 8 mL of blood, the platform detects abnormal methylation in circulating tumor DNA (ctDNA) for non-invasive cancer screening. The pancreatic cancer early detection test is available as an LDT across 44 U.S. states through a CAP-accredited, CLIA-certified laboratory; the breast cancer monitoring test is currently available for research use, with findings presented at the ASCO Annual Meeting.

Menu

OkaiDx Cancer Early Detection Blood Test

Characteristic

Other Products

Products you may be interested in

Highest Rated Products